Reminder: Bayer Head of Pharma *TODAY* Barclays Conversations with the C-Suite in European Healthcare 2026

Research evidence excerpt

Reminder: Bayer Head of Pharma *TODAY* Barclays Conversations with the C-Suite in European Healthcare 2026

company or an investment and so different values may be placed on certain sustainability credentials

as well as adverse ESG-related impacts of companies and ESG controversies. The evolving nature of

sustainable investing considerations, models and methodologies means it can be challenging to

definitively and universally classify a company or investment under a sustainable investing label and

there may be areas where such companies and investments could improve or where adverse ESG-

related impacts or ESG controversies exist. The evolving nature of sustainable finance related

regulations and the development of jurisdiction-specific regulatory criteria also means that there is

likely to be a degree of divergence as to the interpretation of such terms in the market. We expect

industry guidance, market practice, and regulations in this field to continue to evolve.

Any information, data, image, or other content including from a third party source contained, referred

to herein or used for whatsoever purpose by Barclays or a third party (“Information”), in relation to

any actual or potential ‘ESG’, ‘sustainable' or equivalent objective, issue, factor or consideration is not

intended to be relied upon for ESG or sustainability classification, regulatory regime or industry

initiative purposes (“ESG Regimes”), unless otherwise stated. Nothing in these materials, including

any images included therein, is intended to convey, suggest or indicate that Barclays considers or

represents any product, service, person or body mentioned in these materials as meeting or qualifying

for any ESG or sustainability classification, label or similar standards that may exist under ESG

Regimes.